About BerGen Bio

Sponsor retains sole responsibility for content.

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinas...

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create new therapeutic options for cancer patients. BerGenBio’s lead product, BGB324, is a selective, potent and orally available small molecule AXL inhibitor. It is in Phase II clinical development, as a single agent and in combination with marketed immuno-oncology drugs, in three cancer indications with blockbuster potential: Acute myeloid leukaemia (AML); Advanced non-small-cell lung cancer (NSCLC); Triple negative breast cancer (TNBC) The Company is also developing a diversified pre-clinical pipeline of selective AXL inhibitors, including biologics and small molecules. BerGenBio intends to develop its drug candidates itself and through strategic partnerships in multiple indications, and retains all options for the future commercialization of its products.

Contact BerGen Bio

Phone Number
+47 559 61 159

More About BerGen Bio

Therapeutic Areas
  • Oncology
Technologies
  • Drug delivery
Company Type
  • Pharmaceutical
State of Ownership
  • Private
Sponsorship Group
  • Networker
Go to the profile of Samia Burridge

Samia Burridge

Business Development Manager, Global Sponsorship, Nature Research Group

Go to the profile of Carmen Ramirez

Carmen Ramirez

Sales Account Executive, Springer Nature

Go to the profile of Albany A. Cordova Martins

Albany A. Cordova Martins

Business Development Executive, Nature Publishing Group, Springer Nature